FDA Issues Warning Letter to Novo Nordisk Over Failure to Properly Report Ozempic-Linked Deaths and Adverse Events

The U.S. Food and Drug Administration has issued a formal warning letter to Novo Nordisk, the Danish pharmaceutical giant behind blockbuster drugs Ozempic and Wegovy, citing significant failures in the company's protocols for reporting adverse events associated with semaglutide, the active compound in both medications. The letter, dated March 5, was triggered by an FDA inspection conducted at Novo Nordisk's U.S. headquarters in Plainsboro, New Jersey, in early 2025, as part of the agency's Bioresearch Monitoring Program — a regulatory framework designed to ensure timely and accurate drug safety reporting. Among the violations identified, the FDA flagged three patient deaths that were allegedly not reported to the agency in accordance with required procedures. One of those deaths was classified as a suicide, and an additional case involved a patient who reported experiencing suicidal ideation while taking the medication. Critically, the FDA stopped short of establishing a causal link between semaglutide and these outcomes, emphasizing instead that its concerns centered on procedural non-compliance rather than conclusions about drug safety. Novo Nordisk responded publicly on Tuesday, stating it had been actively working to address the agency's concerns since the inspection. The company characterized the warning letter as a request for additional documentation regarding corrective steps already undertaken, and maintained that the letter drew no conclusions about the safety or quality of its products. The development arrives amid an evolving regulatory landscape for GLP-1 receptor agonists. In a separate and recent review, the FDA found no established causal link between semaglutide-class drugs and suicidal behavior, and in January moved to remove boxed warnings related to suicidal ideation from these medications. Novo Nordisk pledged to resolve all matters outlined in the warning letter to the FDA's full satisfaction.